Rucaparib Significantly Improved PFS Compared With Chemo In Patients With BRCA-Mutated, Advanced, Relapsed Ovarian Cancer

MD Edge ObGyn  (3/21, Osterweil) reports, “The PARP inhibitor rucaparib significantly improved progression-free survival (PFS) compared with standard-of-care chemotherapy in women with BRCA-mutated, advanced, relapsed ovarian cancer in the phase 3 ARIEL4 study.” The findings from ARIEL4 were presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. MedPage Today  (3/20, Bankhead) reported, “Treatment with rucaparib (Rubraca) led to a median progression-free survival (PFS) of 7.4 months versus 5.7 months with chemotherapy. The advantage persisted in per-protocol and intention-to-treat (ITT) analyses and investigator- and independently assessed PFS.” Cancer Network  (3/20, Astor) also reported.